Old and new prognostic factors in acute myeloid leukemia with deranged core‐binding factor beta. Issue 7 (5th June 2013)

• Record Type: Journal Article
• Authors: Cairoli, Roberto; Beghini, Alessandro; Turrini, Mauro; Bertani, Giambattista; Nadali, Gianpaolo; Rodeghiero, Francesco; Castagnola, Carlo; Lazzaroni, Francesca; Nichelatti, Michele; Ferrara, Felicetto; Pizzolo, Giovanni; Pogliani, Enrico; Rossi, Giuseppe; Martinelli, Giovanni; Morra, Enrica
• Is Part Of: American journal of hematology. Volume 88:Issue 7(2013:Jul.)
• Page Start: 594
• Page End: 600
• Publication Date: 2013-06-05
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23461
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Acute myeloid leukemia (AML) with deranged core‐binding factor beta (CBFβ) is usually associated with a favorable prognosis with 50–70% of patients cured using contemporary treatments. We analyzed the prognostic significance of clinical features on 58 patients with CBFβ‐AML aged ≤60 years. Increasing age was the only predictor for survival (<italic>P</italic> &lt;0.001), with an optimal cut‐point at 43 years. White blood cells (WBCs) at diagnosis emerged as an independent risk factor for relapse incidence (<italic>P</italic> = 0.017), with 1.1% increase of hazard for each 1.0 × 10⁹/L WBC increment. <italic>KIT</italic> mutations lacked prognostic value for survival and showed only a trend for relapse incidence (<italic>P</italic> = 0.069). Am. J. Hematol. 88:594–600, 2013. © 2013 Wiley Periodicals, Inc.</p> </abstract>